ASCO GU 2018: Multimodality Approach to Locally Advanced Bladder Cancer
San Francisco, CA (UroToday.com) The treatment of patients with locally advanced bladder cancer (BC) can often be nuanced, and emerging evidence of improved therapies makes this space difficult to navigate. In this case panel discussion, Dr. Alison Birtle, Dr. Alfred Witjes, and Dr. Dean Bajorin addressed several difficult cases offering their expertise on the optimal management strategy for complex patients with locally advanced bladder cancer.
ASCO GU 2018: Primary Results of NRG/RTOG 0712—A Randomized Phase 2 Multicenter Trial - Selective Bladder Preservation
San Francisco, CA (UroToday.com) While radical cystectomy has historically been the standard of care for patients with muscle-invasive urothelial carcinoma of the bladder, there has recently been increased interest in evaluating bladder-sparing treatment modalities.
ASCO GU 2018: Results of POUT: A Phase III Randomized Trial of Perioperative Chemotherapy versus Surveillance in Upper Tract Urothelial Carcinoma
San Francisco, CA (UroToday.com) The management of patients with upper tract urothelial carcinoma is challenging due to the lack of high-level evidence, which results from the disease’s overall rarity. The standard of care for patients with high-grade disease or those suspected to have invasive disease is a radical nephroureterectomy, with some advocating for the added use neoadjuvant or adjuvant platinum-based chemotherapy. The added benefit of platinum chemotherapy in patients with locally invasive UTUC has been extrapolated from the bladder cancer literature and supported by several retrospective and population reports. Dr. Alison J. Birtle presents results of the first randomized clinical trial in the field for patients with UTUC. The POUT trial which assessed the added benefit of using platinum-based chemotherapy in the adjuvant setting in patients undergoing a radical nephroureterectomy.